Condition: Learning · Cognitive Functioning · Emotional Processing · Sponsor: University of Oxford
In this study, the investigators will examine the effects of blocking the orexin system on human behaviour and brain function using daridorexant, a medication that inhibits orexin activity. Orexin is a brain chemical involved in regulating sleep, emotion, motivation, and stress responses, which are often disrupted in mental health disorders. Healthy volunteers will be randomly assigned to receive a single dose of daridorexant or placebo in a double-blind design. Participants will then complete behavioural and cognitive tasks assessing emotional processing, aversive learning, and executive function. The study aims to clarify the role of orexin in emotional and cognitive processes relevant to conditions such as depression and anxiety.
This description comes directly from the study's public registry record.
Michael J Colwell, DPhil · 01865 618200 · michael.colwell@psych.ox.ac.uk
Daniela A Borges, MD · 01865 618200 · daniela.almeidaborges@psych.ox.ac.uk
Always discuss trial participation with your own doctor first.
| Department of Psychiatry, University of Oxford | Oxford, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07267559